Marathon Pharma's Drug Pricing Is Playing With Fire
Step back, Martin Shkreli: The pharma industry has a new villain.
Marathon Pharmaceuticals LLC, led by CEO Jeffrey Aronin, got FDA approval on Thursday for a steroid to treat Duchenne Muscular Dystrophy (DMD), a rare and deadly muscle-wasting disease. This approval also got the company a valuable FDA voucher it can use to accelerate the review process for a different future drug, or sell to another company for millions of dollars.
Marathon Pharmaceuticals LLC, led by CEO Jeffrey Aronin, got FDA approval on Thursday for a steroid to treat Duchenne Muscular Dystrophy (DMD), a rare and deadly muscle-wasting disease. This approval also got the company a valuable FDA voucher it can use to accelerate the review process for a different future drug, or sell to another company for millions of dollars.